ICPO Foundation co-founded the RLT Angels Association with the aim of growing access to Radiotheranostics to one million patients
Further founding members include the European Association of Nuclear Medicine (EANM), GE…
Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
Significantly more patients treated with Sotyktu achieved ACR and PASI response rates…
Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) Compared to Opdivo Monotherapy…
Patients experienced a 38% reduction in the risk of disease progression or…
U.S. Food and Drug Administration Approves Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo (nivolumab) Indications1,2
Opdivo Qvantig is the first and only subcutaneously administered PD-1 inhibitor1 Given…